In: In vivo CAR-T

DIT101

Tcelltech

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
Reprograms the patient's own immune T cells, inside the body, to hunt one kind of cell, such as cancerous B cells. Standard CAR-T does this in a lab.In vivo CAR-T for blood cancers, target not disclosed
Tested for
Relapsed or Refractory Hematologic Malignancies
Main trialPhase 1
“This study is a single-arm, open-label clinical trial designed to evaluate the safety and tolerability of DIT101 in adults with relapsed or refractory hematologic malignancies and to explore its potential anti-tumor effects. DIT101 is an investigational in vivo CAR-T cell therapy administered by intravenous infusion. After administration, it is intended to generate CAR-T cells within the patient's body that can recognize and attack tumor cells. Unlike approved autologous CAR-T therapies, DIT101 does not require collection and ex vivo genetic modification of the participant's own cells. The…”In the company’s words, NCT07485504 on ClinicalTrials.gov

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting 15 Oct 2028 Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026

Follow DIT101

Following is part of Solo: you see every change to DIT101 the day it happens.

Solo

$49a month

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in